LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION
Important Information Regarding Section 20(a) Individual Liability Claims
RARE INVESTOR ALERT
NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) of a pending securities class action. To be considered for lead plaintiff, investors must file by April 6, 2026.
- Class Period: August 3, 2023 through December 26, 2025
Click here to participate in this action or contact Joseph E. Levi, Esq. at [email protected] | (212) 363-7500.
The Named Individual Defendants
Two senior executives of Ultragenyx are named as individual defendants in the securities class action:
- Emil D. Kakkis, Founder, President, Chief Executive Officer, and Director
- Eric Crombez, Chief Medical Officer and Executive Vice President
The pleading asserts that these individuals, because of their positions, possessed the power and authority to control the contents of the Company's SEC filings, press releases, and presentations to analysts and investors.
Section 20(a) Control Person Framework
As averred in the complaint, Section 20(a) of the Securities Exchange Act imposes liability on persons who control entities that violate the securities laws. The complaint charges that the Individual Defendants acted as controlling persons by reason of their senior management positions and ability to direct the Company's public statements.
Get started on your claim or call (212) 363-7500.
Alleged Control Person Liability
- The individual defendants allegedly had the power to direct the contents of SEC filings and press releases
- As averred, they were provided with copies of reports and releases prior to issuance and could prevent or correct misleading statements
- The complaint charges that they had access to material non-public information about study progress and risks
- The pleading asserts their positions gave them knowledge that positive representations were allegedly false when made
Sarbanes-Oxley Certification Obligations
The Sarbanes-Oxley Act requires senior executives to certify the accuracy of periodic reports filed with the SEC. Sections 302 and 906 impose personal responsibility on certifying officers. The complaint alleges that the individual defendants signed certifications while allegedly knowing the Company's public statements were materially misleading.
"Corporate officers have a duty to ensure their companies' public statements are accurate and complete," noted Joseph E. Levi, Esq. "We are examining the individual defendants' roles in the alleged misconduct."
Levi & Korsinsky, LLP --- Top 50 securities litigation firm (ISS Securities Class Action Services, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors nationwide.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
(212) 363-7500
SOURCE Levi & Korsinsky, LLP
Share this article